Please ensure Javascript is enabled for purposes of website accessibility

Stock Markets Fall Sharply Thursday Morning as Weak Earnings Hit Bed Bath & Beyond, Walgreens Hard

By Dan Caplinger – Jul 9, 2020 at 11:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A steep descent came after more bad news on the employment front.

The stock market has done well lately, but Thursday morning brought a quick reversal to its recent gains. New data showed that first-time claims for unemployment benefits remained at elevated levels, with this week's 1.31 million number extending a streak of more than 1 million claims every single week since mid-March. Just after 11 a.m. EDT, the Dow Jones Industrial Average (^DJI -1.62%) was down 409 points to 25,658. The S&P 500 (^GSPC -1.72%) had fallen 39 points to 3,131, and the Nasdaq Composite (^IXIC -1.80%) had dropped 69 points to 10,424.

Earnings season is just about to ramp up again, and a couple of companies got an early start on telling investors how they're faring. Unfortunately, both Bed Bath & Beyond (BBBY -5.92%) and Walgreens Boots Alliance (WBA -1.47%) weren't able to satisfy their shareholders. That could set a negative tone that could dampen hopes for a summer stock market rally.

Bad beyond expectations

Bed Bath & Beyond's shares plunged 23% Thursday morning as investors reacted to its release of fiscal first-quarter results late Wednesday night. It wasn't surprising to see the home goods retailer's numbers come in weak, but the extent of that weakness shocked many who follow the stock.

Top of storefront showing Bed Bath & Beyond logo.

Image source: Bed Bath & Beyond.

Bed Bath & Beyond's sales plunged by nearly half during the quarter, with temporary store closures being the primary reason for the drop. Even an 82% rise in sales from the retailer's digital channels wasn't enough to ease the damage. The company lost more than $300 million, which was worse than most had expected.

It's always a bad sign when a company leads its press release with a statement on its liquidity, and that's what Bed Bath & Beyond did. The retailer assured investors that cash and short-term investments of $1.2 billion and a new $850 million asset-backed credit facility should help it weather the pandemic's financial impacts. But investors are more worried that the problems that existed long before the coronavirus appeared could end up being insurmountable under current circumstances.

CEO Mark Tritton tried to focus on improved performance in June after the end of the fiscal quarter. However, Bed Bath & Beyond didn't provide an outlook for the remainder of the year, and that signals continued uncertainty about how well the retailer will be able to recover.

Walgreens doesn't look as healthy as hoped

For Walgreens Boots Alliance, today's 10% drop is also related to COVID-19's impacts. Fiscal third-quarter results showed signs of weakness, and Walgreens was careful to warn that there could be further damage from the pandemic in the rest of 2020.

COVID-19 cost Walgreens between $700 million and $750 million during the quarter, with most of the pain coming from non-U.S. operations. Just about all of that reduced revenue fell down to the operating income line, costing the company about $0.61 to $0.65 per share in prospective earnings. As a result, revenue inched higher by just 0.1%, and adjusted earnings per share plunged 44% from year-ago levels.

Interestingly, Walgreens' domestic business held up reasonably well. U.S. retail pharmacy sales were higher on increased consumer spending on brand-name drugs and specialty prescriptions. However, the U.K. market remains extremely weak, and Walgreens warned that it could prove to be a headwind to results in the fiscal fourth quarter as well.

Investors are still weighing what net impact the coronavirus pandemic will have on drugstore retail chains like Walgreens. For now, though, they're adopting a conservative view, and the stock price is adjusting lower as a result.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.83 (-1.47%) $0.49
Bed Bath & Beyond Inc. Stock Quote
Bed Bath & Beyond Inc.
BBBY
$6.67 (-5.92%) $0.42
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$29,590.41 (-1.62%) $-486.27
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$3,693.23 (-1.72%) $-64.76
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$10,867.93 (-1.80%) $-198.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.